1. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen- specific immunotherapy 
Gabriele Di Lorenzo, MD, Pasquale Mansueto, MD, Maria Luisa Pacor, MD, Manfredi Rizzo, MD, Francesco Castello, MD, Nicola Martinelli, MD, Vito Ditta, MD, Claudia Lo Bianco, MD, Maria Stefania Leto-Barone, MD, Alberto D'Alcamo, MD, Gaetana Di Fede, MD, Giovam Battista Rini, MD, Anne Marie Ditto, MD 
Journal of Allergy and Clinical Immunology 
Volume 123, Issue 5, Pages e4 (May 2009)
DOI: /j.jaci
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
ROC curves obtained with serum t-IgE levels (decision point, ≤133 kU/L; sensitivity, 69.7%; and specificity, 67.9%), serum s-IgE levels (decision point, 9.5 kAU/L; sensitivity, 91.0%; specificity, 46.3%), b-eos counts (decision point, 0.43 cells × 10−3 μL; sensitivity, 87.6%; specificity, 57.5%), and serum s-IgE/serum t-IgE ratios (decision point, 16.2%; sensitivity, 97.2%; specificity, 88.1%) by plotting sensitivity in patients with an effective response to ASI versus 100-specificity in patients with an ineffective response to ASI.
Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Sensitivity (Sens) and specificity (Spec) calculated for each allergen used for ASI by using the ratio of serum s-IgE/serum t-IgE of 16.2% as the decision point. A, grass; B, Parietaria judaica; C, Olea europa; D, house dust mites (HDM).
Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Graphic representation of means of VAS (± SD) with regard to A, rhinitis and B, asthma symptoms, respectively.
Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions